Abstract
A total of 15 patients with refractory multiple myeloma (MM; 4 primary unresponsive and 11 relapsed and resistant to re-induction/salvage therapy) received i.v. vincristine on day 1 and oral etoposide daily for 4 days, the treatment being repeated at 3-weekly intervals. The patients were re-assessed after three cycles of chemotherapy, and non-responders received no further therapy. There was no complete or partial response. A minimal response was seen in two patients, and two others showed stable disease. None of the responses was sustained, and all patients eventually had progressive disease. It is concluded that combination chemotherapy with vincristine and oral etoposide given by this schedule is unlikely to be of any value in refractory myeloma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alberto DS, Durie BGM, Salmon SE (1977) Treatment of multiple myeloma in remission with anticancer drugs having cell cycle specific characteristics. Cancer Treat Rep 61: 381
Alexanian R, Dimopoulos M, Barlogie B, Vadhan RS, Champlin R (1991) Chemotherapy for resistant and relapsing multiple myeloma. In: Pileri A, Boccadoro M (eds) Multiple myeloma from biology to therapy — abstracts of the IIIrd International Workshop, Turin. p 105
Barlogie B, Smith L, Alexanian R (1984) Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 310: 1353
Barlogie B, Velasquez WS, Alexanian R, Cabanillas F (1989) Etoposide, dexamethasone, cytarabine and cisplatin in vincristine, doxorubicin and dexamethasone refractory myeloma. J Clin Oncol 7: 1514
Dalton WS, Salmon SE (1992) Drug resistance in myeloma: mechanisms and approaches to circumvention. Haematol Oncol Clin North Am 6: 383
Durie BGM, Salmon SE (1982) The current status and future prospects of treatment for multiple myeloma. Clin Haematol 11: 181
Gore ME, Viner C, Meldrum M, Bell J, Milan S, Zuiable A, Slevin M, Selby PJ, Clark PI, Millar B, Maitland JA, Judson IR, Tillyer C, Malpas JS, McElwain TJ (1989) Intensive treatment of multiple myeloma and criteria for complete remission. Lancet II: 879
Leoni F, Ciolli S, Salti F, Teodori P, Ferrini PR (1991) Teniposide, dexamethasone and continuous-infusion cyclophosphamide in advanced refractory myeloma. Br J Haematol 77: 180
Salmon SE, Haut A, Bonnet JD, Amare M, Weick JK, Durie BM (1983) Alternating combination chemotherapy improves survival in multiple myeloma — a South-West Oncology Group study. J Clin Oncol 1: 453
WHO (1979) Handbook for reporting results of cancer treatment. Offset publication 45. WHO, Geneva
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ganjoo, R.K., Williams, A. & Malpas, J.S. Vincristine and oral etoposide in refractory multiple myeloma. Cancer Chemother. Pharmacol. 35, 343–344 (1995). https://doi.org/10.1007/BF00689456
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF00689456